Efficacy and safety of ribonucleic acid for injection Ⅱ combined with chemotherapy in treatment of advanced non-small cell lung cancer: a multicenter, retrospective and controlled study
10.3760/cma.j.cn115355-20210119-00041
- VernacularTitle:注射用核糖核酸Ⅱ联合化疗治疗晚期非小细胞肺癌效果及安全性的多中心回顾性对照研究
- Author:
Zhipeng HAO
1
;
Xiangning FU
;
Shuang MA
;
Yongli YANG
Author Information
1. 华中科技大学同济医学院附属同济医院胸外科，武汉 430030
- Keywords:
Carcinoma, non-small-cell lung;
Drug therapy, combination;
Ribonucleic acid for injection Ⅱ;
Retrospective studies
- From:
Cancer Research and Clinic
2021;33(7):485-491
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of ribonucleic acid for injection Ⅱ combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods:Based on the LinkDoc database, 2 111 patients who were diagnosed with stage Ⅲ B and Ⅳ NSCLC in 8 research centers such as Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology from January 2014 to December 2017 were included. Patients were divided into observation group (1 039 cases) and control group (1 072 cases) according to whether or not they had used ribonucleic acid for injection Ⅱ during chemotherapy. Inverse probability of treatment weighting was used to correct the confounding factors of patients, and there were 1 078 cases in the control group and 1 033 cases in the observation group; the overall survival (OS), progression-free survival (PFS) and the occurrence of adverse events and chemotherapy-related adverse reactions were compared between the two groups. Results:The median OS time of the observation group and the control group was 18.51 months and 15.65 months, and the median PFS time was 7.00 months and 5.49 months, and the differences were statistically significant ( P values ??were 0.001 and 0.003). The incidence of adverse events in the observation group was slightly higher than that in the control group [75.6% (781/1 033) vs. 74.1% (799/1 078)], and the incidence of chemotherapy-related adverse reactions in the observation group was slightly higher than that in the control group [43.9% (453/1 033) vs. 40.7% (439/1 078)], but the differences were not statistically significant (both P > 0.05). Conclusions:Ribonucleic acid for injection Ⅱ can prolong the OS and PFS time of patients with stage Ⅲ B and Ⅳ NSCLC receiving chemotherapy. It is safe and can increase the clinical benefit of patients to a certain extent.
